FROM STEPHEN

SEC source: 0001213900-25-074538 · ownership.xml · derivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 297,600

Underlying: Class A Common Stock · 297,600 shares

Expires 2035-08-06

F1 · derivative.exercise_date: The shares underlying this option vest as to 25% of the award on August 7, 2026, with the remainder vesting in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each applicable vesting date.

SEC source: 0001104659-22-001942 · tm222161-1_4seq1.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,693

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2022.

SEC source: 0001104659-21-147638 · tm2134911d2_4seq1.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,019

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2021.

SEC source: 0001104659-21-133655 · tm2131814-3_4seq1.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,292

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2021.

SEC source: 0001104659-21-123265 · tm2129310d1_4seq1.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,542

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 10/01/2021.

SEC source: 0001104659-21-112942 · tm2126978-3_4seq1.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,791

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 09/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.81, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-100200 · tm2124160d4_4seq1.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,044

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 08/01/2021.

SEC source: 0001104659-21-089442 · tm2121558d1_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,305

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.75, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-077766 · tm2119042d4_4seq1.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,182

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 06/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.19 to $4.39, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-061950 · tm2115347d4_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,060

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 05/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.13 to $4.48, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-048716 · tm2112624-4_4seq1.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,949

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 04/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.94, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-032768 · tm218853-4_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,848

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 03/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.46 to $5.51, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-011851 · tm215262-9_4seq1.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,746

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.34 to $6.42, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-011851 · tm215262-9_4seq1.xml · derivative · entry 2

FROM STEPHEN · CIK 0001620137 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-02-01

F3 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-21-000935 · tm211689-4_4seq1.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,288

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.85 to $4.88, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-133325 · tm2038041-3_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,993

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.76 to $3.80, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-120955 · tm2034888d4_form4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,581

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2020.

SEC source: 0001104659-20-112303 · tm2032523-4_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,204

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 10/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.88 to $3.94, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-102300 · tm2030216d4_form4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,835

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 09/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.93 to $3.94, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-090919 · tm2026743-3_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,463

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 08/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.11 to $4.12, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-081227 · tm2024119-4_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,078

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/01/2020.

SEC source: 0001104659-20-069826 · tm2021837-4_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,703

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 06/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.11 to $5.2202, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-057468 · tm2018856d1_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,330

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 05/01/2020.

SEC source: 0001104659-20-043263 · tm2014998d3_form4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,947

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 04/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.96 to $5.12, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-031499 · tm2012338d4_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,617

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 03/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.05, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-022849 · tm209305-9_4.xml · derivative · entry 2

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-02-14

F2 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2021, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-20-022849 · tm209305-9_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,329

F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on February 1, 2021, and the remaining balance will vest monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-20-011342 · tm206871d4_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,329

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2020.

SEC source: 0001104659-20-001639 · tm201302-4_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,913

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.395 to $9.52, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-19-075128 · tm1926709d1_form4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,643

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.46 to $7.48, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-19-061122 · tm1922166-2_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,296

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.85 to $4.00, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001144204-19-048122 · tv530955_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,966

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 09/01/2019 and 10/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.89 to $3.02, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · balance_after: Effective as of 08/30/2019, the Issuer effected a 1-for-15 reverse split of its common stock. The number of shares reflects the reverse stock split.

SEC source: 0001144204-19-038335 · tv527078_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,022,259

SEC source: 0001144204-19-034763 · tv525229_4.xml · nonDerivative · entry 3

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,032,465

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/10/2019.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.227 to $0.2403, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.

SEC source: 0001144204-19-034763 · tv525229_4.xml · nonDerivative · entry 2

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,074,917

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/10/2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2257 to $0.24, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

SEC source: 0001144204-19-034763 · tv525229_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,117,369

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 07/10/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.245, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001144204-19-005043 · tv512443_form4.xml · derivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2029-02-01

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2020, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001144204-18-038190 · tv498481_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,159,820

F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The restrictions will vest as to one-third (1/3) of the shares on July 10, 2019, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001144204-18-021206 · tv491363_4.xml · derivative · entry 2

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2023-04-17

F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $0.32 per share of common stock and warrant in connection with the Issuer's public offering that closed on April 17, 2018. Each warrant will be exercisable during the period commencing on April 17, 2018 and ending on April 17, 2023 at an exercise price of $0.32.

SEC source: 0001144204-18-021206 · tv491363_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 409,820

F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $0.32 per share of common stock and warrant in connection with the Issuer's public offering that closed on April 17, 2018. Each warrant will be exercisable during the period commencing on April 17, 2018 and ending on April 17, 2023 at an exercise price of $0.32.

SEC source: 0001144204-18-012234 · tv487514_4.xml · derivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2028-02-28

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 28, 2019, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001144204-18-000492 · tv482535_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 284,820

F1 · kind: The shares were acquired under the Issuer's Employee Stock Purchase Plan on December 29, 2017 in a transaction exempt under Rule 16b-3(c).

SEC source: 0001144204-17-042118 · v473009_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,465

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9901 to $1.03, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

SEC source: 0001144204-17-033630 · v469455_4.xml · derivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2027-06-21

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on June 21, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001144204-17-032552 · v469021_form4.xml · derivative · entry 2

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2022-06-14

F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $1.50 per share of common stock and warrant in connection with the Issuer's public offering that closed on June 14, 2017. Each warrant will be exercisable during the period commencing on June 14, 2017 and ending on June 14, 2022 at an exercise price of $1.50.

SEC source: 0001144204-17-032552 · v469021_form4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 259,965

F1 · price: The reported securities were purchased by the reporting person for a combined purchase price of $1.50 per share of common stock and warrant in connection with the Issuer's public offering that closed on June 14, 2017. Each warrant will be exercisable during the period commencing on June 14, 2017 and ending on June 14, 2022 at an exercise price of $1.50.

SEC source: 0001144204-17-028874 · v467586_4.xml · derivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2027-05-18

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option became exercisable immediately upon grant.

SEC source: 0001144204-17-006500 · v458598_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,965

F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The restrictions will vest as to one-third (1/3) of the shares on February 6, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001144204-16-124265 · v448959_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,965

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.479 to $1.509, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.